Potential sex differences in activation of pain-related brain regions in nonhuman primates with a unilateral spinal nerve ligation.

Macaca fascicularis biomarkers functional magnetic resonance imaging lumbar radicular pain neuroimaging neuropathic pain sciatica straight leg raise

Journal

Neural regeneration research
ISSN: 1673-5374
Titre abrégé: Neural Regen Res
Pays: India
ID NLM: 101316351

Informations de publication

Date de publication:
Nov 2023
Historique:
medline: 7 6 2023
pubmed: 7 6 2023
entrez: 7 6 2023
Statut: ppublish

Résumé

The lack of truly robust analgesics for chronic pain is owed, in part, to the lack of an animal model that reflects the clinical pain state and of a mechanism-based, objective neurological indicator of pain. The present study examined stimulus-evoked brain activation with functional magnetic resonance imaging in male and female cynomolgus macaques following unilateral L7 spinal nerve ligation and the effects of clinical analgesics pregabalin, duloxetine, and morphine on brain activation in these macaques. A modified straight leg raise test was used to assess pain severity in awake animals and to evoke regional brain activation in anesthetized animals. The potential effects of clinical analgesics on both awake pain behavior and regional brain activation were examined. Following spinal nerve ligation, both male and female macaques showed significantly decreased ipsilateral straight leg raise thresholds, suggesting the presence of radicular-like pain. Morphine treatment increased straight leg raise thresholds in both males and females whereas duloxetine and pregabalin did not. In male macaques, the ipsilateral straight leg raise activated contralateral insular and somatosensory cortex (Ins/SII), and thalamus. In female macaques, the ipsilateral leg raise activated cingulate cortex and contralateral insular and somatosensory cortex. Straight leg raises of the contralateral, unligated leg did not evoke brain activation. Morphine reduced activation in all brain regions in both male and female macaques. In males, neither pregabalin nor duloxetine decreased brain activation compared with vehicle treatment. In females, however, pregabalin and duloxetine decreased the activation of cingulate cortex compared with vehicle treatment. The current findings suggest a differential activation of brain areas depending on sex following a peripheral nerve injury. Differential brain activation observed in this study could underlie qualitative sexual dimorphism in clinical chronic pain perception and responses to analgesics. Future pain management approaches for neuropathic pain will need to consider potential sex differences in pain mechanism and treatment efficacy.

Identifiants

pubmed: 37282478
pii: NeuralRegenRes_2023_18_11_2466_371382
doi: 10.4103/1673-5374.371382
pmc: PMC10360086
doi:

Types de publication

Journal Article

Langues

eng

Pagination

2466-2473

Déclaration de conflit d'intérêts

None

Références

Spine (Phila Pa 1976). 2009 Jul 1;34(15):1585-9
pubmed: 19564769
Pain. 2004 Sep;111(1-2):151-61
pubmed: 15327819
BJA Educ. 2022 Sep;22(9):343-349
pubmed: 36033931
Biomedicines. 2022 Oct 28;10(11):
pubmed: 36359264
Pain. 2012 Sep;153(9):1837-1846
pubmed: 22727500
Mol Pharmacol. 2014 Oct;86(4):430-7
pubmed: 25106425
J Neurosci Methods. 2021 Jan 15;348:108997
pubmed: 33188801
Sci Rep. 2022 May 3;12(1):7192
pubmed: 35504949
Brain Res Bull. 2022 Sep;187:122-137
pubmed: 35781031
J Pain. 2004 Mar;5(2):92-103
pubmed: 15042517
Neuron. 2015 May 6;86(3):617-31
pubmed: 25950631
Pain. 2021 Apr 1;162(4):1176-1187
pubmed: 33021770
Prog Neurobiol. 1999 Jan;57(1):1-164
pubmed: 9987804
CNS Neurol Disord Drug Targets. 2018;17(5):348-360
pubmed: 29766827
Pain Med. 2007 Jul-Aug;8(5):397-409
pubmed: 17661853
Eur J Pharmacol. 2014 Jul 15;735:17-25
pubmed: 24726848
J Anat. 2005 Jul;207(1):19-33
pubmed: 16011543
Neuroimage. 2018 May 15;172:642-653
pubmed: 29421324
Hum Brain Mapp. 2021 Feb 15;42(3):598-614
pubmed: 33068500
Trials. 2011 Feb 28;12:55
pubmed: 21356040
J Pharmacol Exp Ther. 2020 Jul;374(1):161-174
pubmed: 32321743
Naunyn Schmiedebergs Arch Pharmacol. 2015 Apr;388(4):451-63
pubmed: 25640188
Pain. 1994 Feb;56(2):155-166
pubmed: 8008406
Sci Rep. 2017 Jun 27;7(1):4305
pubmed: 28655928
Neuropharmacology. 2019 May 1;149:204-211
pubmed: 30817933
J Pain. 2018 Jun;19(6):571-588
pubmed: 29307749
J Neurosci Res. 2017 Jan 2;95(1-2):500-508
pubmed: 27870397
Pharmacol Biochem Behav. 2005 May;81(1):170-81
pubmed: 15894076
Aten Primaria. 2022 Jan;54(1):102144
pubmed: 34637958
Pain Rep. 2019 Aug 07;4(4):e732
pubmed: 31579844
Br J Anaesth. 2018 Feb;120(2):299-307
pubmed: 29406179
Mol Pain. 2021 Jan-Dec;17:17448069211008697
pubmed: 33853400
Hum Reprod. 2019 Mar 1;34(3):469-478
pubmed: 30597044
Front Neuroanat. 2013 Apr 09;7:3
pubmed: 23576961
Osteoarthritis Cartilage. 2016 Jul;24(7):1190-9
pubmed: 26944197
J Neurosci Res. 2017 Jan 2;95(1-2):604-616
pubmed: 27870423
Br J Anaesth. 1975 Dec;47(12):1265-7
pubmed: 1218165
JAMA. 2013 Apr 3;309(13):1359-67
pubmed: 23549581
Nat Rev Neurol. 2020 Jul;16(7):381-400
pubmed: 32541893
Methods Enzymol. 2004;385:91-102
pubmed: 15130735
J Am Assoc Lab Anim Sci. 2020 Jan 1;59(1):94-103
pubmed: 31753062

Auteurs

Kanae Murata (K)

Hamamatsu Pharma Research, Inc., Hamamatsu, Shizuoka, Japan.

Kenya Nozawa (K)

Hamamatsu Pharma Research, Inc., Hamamatsu, Shizuoka, Japan.

Mayumi Matsushita (M)

Hamamatsu Pharma Research, Inc., Hamamatsu, Shizuoka, Japan.

Aozora Yamashita (A)

Hamamatsu Pharma Research, Inc., Hamamatsu, Shizuoka, Japan.

Rintaro Fujii (R)

Hamamatsu Pharma Research, Inc., Hamamatsu, Shizuoka, Japan.

Yuji Awaga (Y)

Hamamatsu Pharma Research, Inc., Hamamatsu, Shizuoka, Japan.

Aldric Hama (A)

Hamamatsu Pharma Research, Inc., Hamamatsu, Shizuoka, Japan.

Takahiro Natsume (T)

Hamamatsu Pharma Research, Inc., Hamamatsu, Shizuoka, Japan.

Go Yoshida (G)

Department of Orthopedic Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.

Yukihiro Matsuyama (Y)

Department of Orthopedic Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.

Hiroyuki Takamatsu (H)

Hamamatsu Pharma Research, Inc., Hamamatsu, Shizuoka, Japan.

Classifications MeSH